Patent ID: 8969315
Filing Date: 2015-03-03
Classification: A61K,A61P,C12N

Abstract:
1. A method of treating an individual having or at risk of developing a disease, disorder or condition having an inflammatory component, comprising administering to the individual a therapeutically effective amount of enhanced placental stem cells, wherein said enhanced placental stem cells comprise or have been contacted with an effective amount of modulatory RNA molecules that decrease expression of one or more human nuclear receptors in said enhanced placental stem cells, resulting in suppression of soluble IL-23 protein produced by peripheral blood mononuclear cells (PBMCs) in the presence of said enhanced placental stem cells compared to placental stem cells not contacted with said modulatory RNA molecules, wherein said modulatory RNA molecules are small interfering RNAs (siRNAs), microRNA inhibitors (miR inhibitors), or micro RNA mimics (miR mimics), wherein said one or more human nuclear receptors is selected from the group consisting of: vitamin D receptor (VDR); nuclear receptor subfamily 4, group A, member 3 (NR4A3); nuclear receptor subfamily 0, group B, member 2 (NR0B2); nuclear receptor subfamily 1, group 1, member 2 (NR1I2); nuclear receptor subfamily 1, group H, member 3 (NR1H3); and deoxynucleotidyltransferase, terminal, interacting protein 1 (DNTTIP1), and wherein the therapeutically effective amount is an amount sufficient to cause a detectable improvement in one or more symptoms of said disease, disorder or condition.